---
title: "Wegovy (semaglutide) in chronic weight management: Safety questions"
description: "Safety questions on Wegovy (semaglutide) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: What are the most common side effects of Wegovy? How do Wegovy HD 7.2 mg side effects compare with 2.4 mg? What are the side effects of the Wegovy pill? How long do Wegovy pill side effects such as nausea last? 7 further questions follow. 11 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide) in chronic weight management: Safety questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)

Safety questions that apply to every indication of Wegovy are on [Wegovy (semaglutide), all indications: Safety](https://www.evicenter.com/medical-information/wegovy/safety).

## Side effects

<a id="wegovy-side-effects"></a>

### What are the most common side effects of Wegovy?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “The most common adverse reactions for Wegovy<sup>®</sup> (incidence ≥5%) are nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss.<sup>1</sup>”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=The%20most%20common%20adverse%20reactions,gastroesophageal%20reflux%20disease%2C%20and%20hair)

> “Table 3 shows adverse reactions reported in greater than or equal 
> to 2% of WEGOVY<sup>®</sup> 2.4 mg injection-treated adult patients and 
> more frequently than in the placebo group from these trials.
> Table 3. Adverse Reactions (≥2% and Greater Than 
> Placebo) in WEGOVY<sup>®</sup> 2.4 mg Injection-
> treated Adults with Obesity or Overweight for 
> Weight Reduction
> Placebo 
> N=1,261
> %
> WEGOVY<sup>®</sup> 
> Injection (2.4 mg 
> Once Weekly)
> N=2,116
> %
> Nausea
> 16
> 44
> Diarrhea
> 16
> 30
> Vomiting
> 6
> 24
> Constipation
> 11
> 24
> Abdominal Pain<sup>a</sup>
> 10
> 20
> Headache
> 10
> 14
> Fatigue<sup>b</sup>
> 5
> 11
> Dyspepsia
> 3
> 9
> Dizziness
> 4
> 8
> Abdominal Distension
> 5
> 7
> Eructation 
> <1
> 7
> Hypoglycemia in T2DM<sup>c</sup>
> 2
> 6
> Flatulence
> 4
> 6
> Gastroenteritis
> 4
> 6
> Gastroesophageal Reflux 
> Disease
> 3
> 5
> Gastritis<sup>d</sup>
> 1
> 4
> Gastroenteritis Viral
> 3
> 4
> Hair Loss
> 1
> 3
> Dysesthesia<sup>e</sup>
> 1
> 2
> <sup>a</sup> Includes abdominal pain, abdominal pain upper, abdominal pain lower, 
> gastrointestinal pain, abdominal tenderness, abdominal discomfort and 
> epigastric discomfort.
> <sup>b</sup> Includes fatigue and asthenia.
> <sup>c</sup> Defined as blood glucose <54 mg/dL with or without symptoms of 
> hypoglycemia or severe hypoglycemia (requiring the assistance of another 
> person) in patients with type 2 diabetes not on concomitant insulin (Study 3, 
> WEGOVY<sup>®</sup> N=403, Placebo N=402). See text below for further information 
> regarding hypoglycemia in patients with and without type 2 diabetes. T2DM = 
> type 2 diabetes mellitus.
> <sup>d</sup> Includes chronic gastritis, gastritis, gastritis erosive, and reflux gastritis.
> <sup>e</sup> Includes paresthesia, hyperesthesia, burning sensation, allodynia, 
> dysesthesia, skin burning sensation, pain of skin, and sensitive skin.”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

Note: Table 3 columns are placebo (N=1,261) then WEGOVY 2.4 mg injection (N=2,116), in % of patients, pooled from 3 placebo-controlled weight-reduction trials in adults.

<a id="wegovy-side-effects-7-2-mg"></a>

### How do Wegovy HD 7.2 mg side effects compare with 2.4 mg?

Applies to: Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

> “The safety of WEGOVY<sup>®</sup> 7.2 mg injection was evaluated in two 
> 72-week double-blinded randomized placebo-controlled 3-armed 
> trials (Study 8 and Study 9), including 1,311 patients with obesity 
> (BMI ≥30 kg/m<sup>2</sup>) exposed in the treatment arm with WEGOVY<sup>®</sup> 
> 7.2 mg injection, 304 patients exposed in the treatment arm with 
> WEGOVY<sup>®</sup> 2.4 mg injection, and 303 patients exposed to placebo 
> [see Clinical Studies (14.2)]. After dosage escalation, 1,149 patients 
> received at least one dose of WEGOVY<sup>®</sup> 7.2 mg injection, and 578 
> patients received 7.2 mg for at least 1 year. Baseline characteristics 
> in the WEGOVY<sup>®</sup> 7.2 mg injection arm included a mean age of 49 
> years, 70% female, 85% White, 5% Asian, 8% Black or African 
> American, and 2% reported as other or unknown; and 5% were 
> Hispanic or Latino ethnicity. At baseline, mean BMI was 39.5 kg/
> m<sup>2</sup>, 52% with hypertension, 38% with dyslipidemia, 40% with a 
> BMI greater than 40 kg/m<sup>2</sup>, and 14% with CV disease.
> In these clinical trials, 5% of patients treated with 7.2 mg WEGOVY<sup>®</sup> 
> injection, 5% of patients treated with 2.4 mg of WEGOVY<sup>®</sup> injection 
> and 2% of patients treated with placebo permanently discontinued 
> treatment as a result of adverse reactions. The most common 
> adverse reactions leading to discontinuation were gastrointestinal 
> disorders: 3%, 3%, and 0.3%, for WEGOVY<sup>®</sup> 7.2 mg injection, 
> WEGOVY<sup>®</sup> 2.4 mg injection, and placebo, respectively.
> Table 4 shows adverse reactions reported in greater than or equal 
> to 2% of WEGOVY<sup>®</sup> 7.2 mg injection and more frequently than 
> 2.4 mg injection-treated and placebo-treated patients from these 
> studies.
> Table 4. Adverse Reactions (2% and Greater Than 
> WEGOVY<sup>®</sup> 2.4 mg and Placebo) in WEGOVY<sup>®</sup> 
> 7.2 mg Injection-treated Adults with Obesity 
> for Weight Reduction
> Placebo
> N=303
> %
> WEGOVY<sup>®</sup> 
> Injection 
> (2.4 mg Once 
> Weekly)
> N=304
> %
> WEGOVY<sup>®</sup> 
> Injection 
> (7.2 mg Once 
> Weekly)
> N=1,311
> %
> Nausea
> 13
> 35
> 39
> Vomiting
> 6
> 16
> 22
> Dysesthesia<sup>a</sup>
> 0
> 6
> 22
> Constipation
> 8
> 19
> 20
> Abdominal pain<sup>b</sup>
> 7
> 9
> 12
> Fatigue<sup>c</sup>
> 5
> 9
> 11
> Headache
> 7
> 8
> 9
> Dizziness<sup>d</sup>
> 1
> 5
> 6
> Hair loss
> 1
> 3
> 6
> Flatulence
> 2
> 2
> 4
> <sup>a</sup> Includes allodynia, burning sensation, dysesthesia, hyperesthesia, 
> hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, 
> skin discomfort, and skin sensitization.
> <sup>b</sup> Includes abdominal pain, abdominal pain upper, abdominal pain lower, 
> gastrointestinal pain, abdominal tenderness, abdominal discomfort and 
> epigastric discomfort.
> <sup>c</sup> Includes fatigue and asthenia.
> <sup>d</sup> Includes dizziness and dizziness postural.”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

Note: Table 4 columns are placebo (N=303), WEGOVY 2.4 mg (N=304), and WEGOVY 7.2 mg (N=1,311), in % of patients. The Clinical Product Review describes the same pool as the STEP UP and STEP UP T2D trials.

<a id="wegovy-side-effects-pill"></a>

### What are the side effects of the Wegovy pill?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “The types and frequency of common adverse reactions were similar to the Wegovy<sup>®</sup> pen<sup>1,7</sup>”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=The%20types%20and%20frequency%20of%20common%20adverse%20reactions%20were%20similar%20to%20the)

On the page, select: Pill

> “In the 64-week OASIS 4 clinical trial:
> 6.9% of patients treated with once-daily Wegovy<sup>®</sup> pill 25 mg and 5.9% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions<sup>1</sup>
> The most common event type leading to discontinuation was gastrointestinal adverse reactions: 3.4% for Wegovy<sup>®</sup> pill vs 2.0% for placebo<sup>1</sup>
> The most common adverse reactions leading to discontinuation (frequency ≥1%) were: nausea (1.5% vs 0%) and sleep disorder (1% and 0%) for the Wegovy<sup>®</sup> pill and placebo<sup>3</sup>”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=In%20the%2064%2Dweek%20OASIS%204,pill%20and)

On the page, select: Pill

> “In the clinical trial with WEGOVY<sup>®</sup> 25 mg tablets, the types and 
> frequency of common adverse reactions were similar to those listed 
> in Table 3.”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

> “In a clinical trial with WEGOVY<sup>®</sup> 25 mg tablets, 5% of WEGOVY<sup>®</sup>-
> treated patients and no placebo-treated patients reported 
> dysesthesia adverse reactions.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

> “In randomized clinical trials in adults for 
> weight reduction, cholelithiasis was reported by 1.6% of WEGOVY<sup>®</sup> 
> injection-treated patients and 0.7% of placebo injection-treated 
> patients, and by 2.5% of WEGOVY<sup>®</sup> tablet-treated patients and 
> 1% of placebo tablet-treated patients.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-pill-side-effect-duration"></a>

### How long do Wegovy pill side effects such as nausea last?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “GI adverse reactions were generally transient and most prevalent during the dose-escalation period<sup>3</sup>
> Median duration of nausea: 13 days for patients on the Wegovy<sup>®</sup> pill vs 12 days for patients on placebo
> Median duration of vomiting: 2 days for patients on the Wegovy<sup>®</sup> pill vs 1 day for patients on placebo
> Median duration of diarrhea: 4 days for patients on the Wegovy<sup>®</sup> pill vs 4 days for patients on placebo
> Median duration of constipation: 26 days for patients on the Wegovy<sup>®</sup> pill vs 127 days for patients on placebo”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=GI%20adverse%20reactions%20were%20generally,127%20days%20for%20patients%20on%20placebo)

On the page, select: Pill

> “The most common adverse reactions leading to discontinuation (frequency ≥1%) were: nausea (1.5% vs 0%) and sleep disorder (1% and 0%) for the Wegovy<sup>®</sup> pill and placebo<sup>3</sup>”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=The%20most%20common%20adverse%20reactions%20leading,pill%20and)

On the page, select: Pill

Note: These median durations are from OASIS 4 (Wegovy 25 mg tablets vs placebo) on the safety profile page of the Wegovy HCP site; the Prescribing Information does not report them.

<a id="wegovy-nausea"></a>

### How common is nausea on the Wegovy injection?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “In clinical trials in adults for weight reduction, 73% of WEGOVY<sup>®</sup> 
> injection-treated patients and 47% of patients receiving placebo 
> reported gastrointestinal adverse reactions, including severe 
> reactions that were reported more frequently among patients 
> receiving WEGOVY<sup>®</sup> injection (4.1%) than placebo (0.9%). The most 
> frequently reported reactions were nausea (44% vs. 16%), vomiting 
> (25% vs. 6%), and diarrhea (30% vs. 16%). Other reactions that 
> occurred at a higher incidence among WEGOVY<sup>®</sup> injection-treated 
> adult patients included dyspepsia, abdominal pain, abdominal 
> distension, eructation, flatulence, gastroesophageal reflux disease, 
> gastritis, hemorrhoids, and hiccups. These reactions were most 
> frequently reported during dosage escalation.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

<a id="wegovy-nausea-duration"></a>

### How long does nausea last on Wegovy HD (STEP UP)?

Applies to: Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

> “Nausea was generally transient<sup>4</sup>
>
> Most occurrences of nausea did not lead to permanent discontinuation of Wegovy<sup>®</sup> HD
>
> STEP UP: Reported nausea (median duration 6 days)”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=Nausea%20was%20generally,nausea%20%28median%20duration%206%20days%29)

> “In STEP UP, nausea was reported in all treatment arms and was most prevalent during the dose-escalation period<sup>4</sup>”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=In%20STEP%20UP%2C%20nausea%20was,most%20prevalent%20during%20the%20dose%2Descalation)

> “Nausea was not prospectively measured at each patient visit in clinical trials.”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=Nausea%20was%20not%20prospectively%20measured%20at%20each%20patient%20visit%20in%20clinical%20trials.)

Note: These passages are from the STEP UP section of the safety profile page of the Wegovy HCP site; STEP UP compared Wegovy HD 7.2 mg, Wegovy 2.4 mg, and placebo. The page text does not state which STEP UP arm the 6-day median nausea duration describes; the accompanying chart is an image.

<a id="wegovy-manage-nausea"></a>

### How can Wegovy nausea and stomach side effects be reduced?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Every patient is different. Here are some general considerations for helping your patients manage nausea<sup>2,3</sup>
>
> Eat bland, low-fat foods such as crackers,
> toast, and rice
>
> Eat foods that contain water, such as soup and gelatin
>
> Don’t lie down after you eat
>
> Eat more slowly
>
> Go outside and get some fresh air”

Source: [WEGOVY: Wegovy® Dosing Information, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/dosing.html#:~:text=Every%20patient%20is%20different.%20Here,and%20get%20some%20fresh%20air)

> “Follow the dosage escalation in Table 1 to reduce the risk 
> of gastrointestinal adverse reactions [see Warnings and 
> Precautions (5.6), Adverse Reactions (6.1)].”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “If patients do not tolerate a dose during dosage escalation, 
> consider delaying dosage escalation for 4 weeks.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

Note: The eating suggestions are from the dosing page of the Wegovy HCP site, which cites published references; they do not appear in the Prescribing Information.

<a id="wegovy-stopping-for-side-effects"></a>

### How many people stop taking Wegovy because of side effects?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “WEGOVY<sup>®</sup> was evaluated for safety in 3 randomized, double-blind, 
> placebo-controlled trials that included 2,116 adult patients with 
> obesity or overweight treated with 2.4 mg WEGOVY<sup>®</sup> injection 
> for up to 68 weeks and a 7-week off-drug follow-up period [see 
> Clinical Studies (14.2)].”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

> “In these clinical trials, 6.8% of patients treated with 2.4 mg 
> WEGOVY<sup>®</sup> injection and 3.2% of patients treated with placebo 
> permanently discontinued treatment as a result of adverse 
> reactions. The most common adverse reactions leading to 
> discontinuation were nausea (1.8% versus 0.2%), vomiting (1.2% 
> versus 0%), and diarrhea (0.7% versus 0.1%) for WEGOVY<sup>®</sup> and 
> placebo, respectively.”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

> “Permanent discontinuation of treatment as a result of a 
> gastrointestinal adverse reaction occurred in 4.3% of WEGOVY<sup>®</sup> 
> injection-treated adult patients versus 0.7% of placebo-treated 
> patients. In a pediatric clinical trial for weight reduction, 2.3% of 
> patients treated with WEGOVY<sup>®</sup> injection versus 1.5% of patients 
> who received placebo discontinued treatment as a result of 
> gastrointestinal adverse reactions.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

> “The safety of WEGOVY<sup>®</sup> 7.2 mg injection was evaluated in two 
> 72-week double-blinded randomized placebo-controlled 3-armed 
> trials (Study 8 and Study 9), including 1,311 patients with obesity 
> (BMI ≥30 kg/m<sup>2</sup>) exposed in the treatment arm with WEGOVY<sup>®</sup> 
> 7.2 mg injection, 304 patients exposed in the treatment arm with 
> WEGOVY<sup>®</sup> 2.4 mg injection, and 303 patients exposed to placebo 
> [see Clinical Studies (14.2)].”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

> “In these clinical trials, 5% of patients treated with 7.2 mg WEGOVY<sup>®</sup> 
> injection, 5% of patients treated with 2.4 mg of WEGOVY<sup>®</sup> injection 
> and 2% of patients treated with placebo permanently discontinued 
> treatment as a result of adverse reactions. The most common 
> adverse reactions leading to discontinuation were gastrointestinal 
> disorders: 3%, 3%, and 0.3%, for WEGOVY<sup>®</sup> 7.2 mg injection, 
> WEGOVY<sup>®</sup> 2.4 mg injection, and placebo, respectively.”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

> “In the clinical trial, 6.9% of patients treated with WEGOVY<sup>®</sup> 25 
> mg tablets and 5.9% patients treated with placebo permanently 
> discontinued treatment as a result of adverse reactions. The most 
> common event type leading to discontinuation was gastrointestinal 
> adverse reactions reported in 3.4% with WEGOVY<sup>®</sup> tablets and 
> 2% with placebo.”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

Note: The last passage is from the trial of WEGOVY 25 mg tablets (Study 7).

<a id="wegovy-hair-loss"></a>

### Does Wegovy cause hair loss?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Hair loss adverse reactions in WEGOVY<sup>®</sup> injection-treated patients 
> were associated with weight reduction. In a pool of studies 2, 3, and 
> 4, hair loss was reported in 3.3% of patients treated with WEGOVY<sup>®</sup> 
> 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with 
> placebo (2% female, 0 male). In a pediatric trial, hair loss was 
> reported in 4% of patients treated with 2.4 mg of WEGOVY<sup>®</sup> and 
> no placebo-treated patients.
> In clinical trials with WEGOVY<sup>®</sup> 7.2 mg injection, hair loss was 
> reported in 5.8% of patients treated with WEGOVY<sup>®</sup> 7.2 mg (8.4% 
> female, 0.2% male), 3.3% of patients treated with WEGOVY<sup>®</sup> 2.4 
> mg (5.4% female, 0 male), and 1.0% of patients on placebo (1.5% 
> female, 0 male). In the WEGOVY<sup>®</sup> 7.2 mg group, 1 event led to 
> permanent treatment discontinuation, 1 event led to temporary 
> interruption, and 5 events led to dose reduction, versus none of 
> these actions in the WEGOVY<sup>®</sup> 2.4 mg or placebo groups.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

<a id="wegovy-dysesthesia-skin-sensitivity"></a>

### Does Wegovy HD 7.2 mg cause skin pain, tingling, or burning (dysesthesia)?

Applies to: Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

> “Dysesthesia, and related events of altered skin sensations including 
> paresthesia, pain of skin, sensitive skin, and burning skin sensation, 
> occurred in clinical trials with WEGOVY<sup>®</sup> injection and tablet. The 
> incidence of dysesthesia with WEGOVY<sup>®</sup> increased with increasing 
> dosage and drug levels in the blood.
> In clinical trials evaluating patients with and without type 2 diabetes 
> mellitus, WEGOVY<sup>®</sup> 7.2 mg injection dysesthesia was reported 
> at a higher rate in the WEGOVY<sup>®</sup> 7.2 mg injection group (22%), 
> compared to WEGOVY<sup>®</sup> 2.4 mg injection (6%) and placebo (0.3%). 
> Among 288 patients who experienced dysesthesia with WEGOVY<sup>®</sup> 
> 7.2 mg injection, 2% permanently discontinued treatment, 8% 
> had temporary interruption, and 23% had dose reduction; most 
> subjects with these actions taken to WEGOVY<sup>®</sup> 7.2 mg injection 
> (permanent discontinuation, temporary interruption, or dose 
> reduction) recovered from the event. When an action was taken 
> with WEGOVY<sup>®</sup>, events resolved faster than the events where no 
> action was taken with WEGOVY<sup>®</sup>. Among patients who experienced 
> dysesthesia with WEGOVY<sup>®</sup> 7.2 mg injection, 18% did not report 
> recovering during the trial duration; in most of the patients who 
> did not recover, the WEGOVY<sup>®</sup> dosage was unchanged and not 
> discontinued. Of the patients who recovered after action taken 
> with WEGOVY<sup>®</sup>, 38 patients were re-escalated to 7.2 mg. Of 
> these 38 patients, 17 (45%) subsequently reported recurrence 
> of dysesthesia.
> In a clinical trial with WEGOVY<sup>®</sup> 25 mg tablets, 5% of WEGOVY<sup>®</sup>-
> treated patients and no placebo-treated patients reported 
> dysesthesia adverse reactions.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

<a id="wegovy-low-blood-pressure"></a>

### Can Wegovy cause low blood pressure or fainting?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Adverse reactions related to hypotension (hypotension, orthostatic 
> hypotension, and decreased blood pressure) were reported in 1.3% 
> of WEGOVY<sup>®</sup>-treated adult patients versus 0.4% of placebo-treated 
> patients and syncope was reported in 0.8% of WEGOVY<sup>®</sup>-treated 
> patients versus 0.2% of placebo-treated patients in clinical trials for 
> weight reduction. Some reactions were related to gastrointestinal 
> adverse reactions and volume loss associated with WEGOVY<sup>®</sup>. 
> Hypotension and orthostatic hypotension were more frequently 
> seen in patients on concomitant antihypertensive therapy. In a 
> clinical trial in pediatric patients aged 12 years and older for weight 
> reduction, hypotension was reported in 2.3% of WEGOVY<sup>®</sup>-treated 
> patients versus 0% in placebo-treated patients.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

## Related pages
- [Medical information: Wegovy (semaglutide): Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/access-and-coverage)
